Digital intensive care reimagined – Clinomic combines medicine, AI, and technology in an open platform solution called MONA. With MONA, the health tech company brings a cloud-native solution to clinics that combines patient data, telemedicine, and AI-supported workflows in an interoperable system. It also enables the secondary use of data, e.g., for AI training. The goal: to increase clinical efficiency, relieve the burden on specialist staff, and improve care at the same time. MONA is the digital partner for anyone who wants to leave outdated systems behind and optimize clinical processes holistically. Instead of proprietary data silos, Clinomic relies on modular architecture, standardized data, an open platform, and complete interoperability.
"We know how it feels when systems create more work than they save. MONA is our answer to fragmented IT, missed opportunities, and inefficient processes. We are building a platform that truly supports medical staff." Dr. Arne Peine, Co-Founder & CTO
With its dense network of clinics, research-strong universities, and excellent funding structures, North Rhine-Westphalia offers an ideal environment for health tech innovations. As part of Scale-up.NRW, Clinomic is leveraging these location advantages to further expand its leading role in digital intensive care medicine.
Innovative cell culture – PL BioScience is setting new standards in cell culture technology. With a unique approach, the company transforms expired blood donations into powerful supplements for stem cell culture and regenerative medicine. The vision: sustainable and safe alternatives to animal products. From research to clinical applications, PL BioScience is addressing one of the greatest challenges in cell therapy. With the world's first scalable bioreactor system for the production of synthetic human platelet lysate (HPL), the company offers a clinically applicable solution that does not require any donor blood. This is the first human-based culture medium that can be produced industrially in high quality. PL BioScience is currently focusing on the GMP-compliant industrialization and automation of production processes.
“With innovative strength and a global perspective, we are shaping the cell therapy of tomorrow: As a networked German company, we are driving forward the development of animal-free cell culture media – with solutions that are scalable, clinically relevant, and in demand worldwide.” Dr. Hatim Hemeda, Co-Founder & CEO
NRW offers ideal conditions for the biotech location of tomorrow. Its central location in Europe and proximity to leading pharmaceutical companies create a strong innovation ecosystem. Particularly valuable: targeted state funding for bioeconomy, life sciences, and high-tech start-ups. With Scale-up.NRW, PL BioScience is accelerating its next phase of growth.